TY - JOUR T1 - Forecast analysis of the epidemics trend of COVID-19 in the United States by a generalized fractional-order SEIR model JF - medRxiv DO - 10.1101/2020.04.24.20078493 SP - 2020.04.24.20078493 AU - Conghui Xu AU - Yongguang Yu AU - YangQuan Chen AU - Zhenzhen Lu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/29/2020.04.24.20078493.abstract N2 - In this paper, a generalized fractional-order SEIR model is proposed, denoted by SEIQRP model, which has a basic guiding significance for the prediction of the possible outbreak of infectious diseases like COVID-19 and other insect diseases in the future. Firstly, some qualitative properties of the model are analyzed. The basic reproduction number R0 is derived. When R0 < 1, the disease-free equilibrium point is unique and locally asymptotically stable. When R0 > 1, the endemic equilibrium point is also unique. Furthermore, some conditions are established to ensure the local asymptotic stability of disease-free and endemic equilibrium points. The trend of COVID-19 spread in the United States is predicted. Considering the influence of the individual behavior and government mitigation measurement, a modified SEIQRP model is proposed, defined as SEIQRPD model. According to the real data of the United States, it is found that our improved model has a better prediction ability for the epidemic trend in the next two weeks. Hence, the epidemic trend of the United States in the next two weeks is investigated, and the peak of isolated cases are predicted. The modified SEIQRP model successfully capture the development process of COVID-19, which provides an important reference for understanding the trend of the outbreak.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the National Nature Science Foundation of China under Grant 61772063, Beijing Natural Science Foundation under Grant Z180005.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesour results are reproducible. Our data sets are from JHU COVID-19 database referenced in the paper. ER -